What You Should Know:
- Today, Sema4, a leader in AI-driven clinical data intelligence, announced that they have partnered with BioSymetrics, to accelerate the advancement of drug discovery and new treatments for patients and pharmaceutical companies.
- Together the two will leverage Sema4’s Centrellis®, one of the largest and fastest-growing integrated health information platforms that includes approximately 12 million de-identified clinical records, and Elion, BioSymetrics’
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
PostEra Secures $24M, Forms $260M AI Lab Collaboration with Pfizer
What You Should Know:
- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced $24M in equity financing to accelerate medicinal chemistry and bring new cures to patients.
- PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform. True to its collaborative ethos, the company today also announced its
Read More
Protai Nabs $8M for AI-Powered Drug Discovery Platform
What You Should Know:
- Protai, a Tel Aviv, Israel-based AI-powered drug discovery startup, today announced its emergence from stealth, along with an $8 million seed financing round co-led by Grove Ventures and Pitango HealthTech.
- Protai empowers drug discovery with proteomics and artificial intelligence to unlock new layers of biological insights and to combat complex diseases.
Proteomics-based Platform for Faster and More Accurate Drug Discovery
Despite the significant
Read More
AWS and Pfizer Accelerate Drug Development and Clinical Manufacturing
What You Should Know:
Amazon Web Services (AWS) announced it is working with Pfizer to create innovative, cloud-based solutions to accelerate drug development and clinical manufacturing for testing in clinical trials.
Today, Amazon Web Services, Inc. (AWS) announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. The companies are
Read More
UPMC Launches Drug Discovery Company Novasenta to Develop Targeted Immunotherapy Drugs for Cancer
What You Should Know:
- UPMC today announced the launch of Novasenta, a drug discovery and development company seeking novel and effective treatments for cancer. Co-founded in late 2018 by Robert Ferris, M.D., Ph.D., Dario Vignali, Ph.D., and Greg Delgoffe, Ph.D., all of the UPMC Hillman Cancer Center and Pitt, Novasenta is currently focused on T-cell targets and rapidly advancing programs with the goal of launching its first clinical trial by the end of 2023.
- Based on years
Read More
Benchling Launches New RNA Capabilities to Accelerate Drug Discovery
What You Should Know:
- Benchling, the leading life sciences cloud, today announced the launch of RNA Therapeutics R&D, a new digital solution that allows scientists to design, analyze, and develop complex RNA therapeutics in a unified cloud platform for the first time.
- More than 1,000 R&D organizations/customers can now accelerate collaboration, speed, and simplicity for RNA research via Benchling — an important advance for biotech.
Biopharmaceutical R&D teams can
Read More
Q1 2021 Health IT/Digital Health PC/VE, M&A, IPOs/ SPACs Activity
The first quarter of 2021 has been one of investor optimism as the vaccine rollout continues ahead of expectations and economic activity begins to accelerate in response. Within the Health IT industry, the already strong investment and M&A trends seen in 2020 have only accelerated. Over the course of the quarter, we observed $7 billion in private equity and venture capital investment across 158 companies.
By comparison, Q1 of 2020 saw $3.2 billion and 127 investments. Health IT
Read More
Exscientia Secures $100M To Expand AI Drug Discovery Platform
What You Should Know:
- Exscientia, leading AI drug discovery company, today announced that it completed its $100 million Series C financing round, with a further $30 million investment from Blackrock.
- This new capital, which will be used to support Exscientia's platform development and proprietary pipeline, follows Exscientia’s demonstrated high growth, having announced earlier this year that the first ever precision engineered drug designed using AI had entered Phase I human clinical
Read More
Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development
What You Should Know:
- Global biopharma company UCB and Microsoft announced today a new, multi-year strategic collaboration to advance UCB’s digital transformation, change the way care is delivered, and accelerate better outcomes for people living with severe diseases.
- The partnership builds on the companies’ joint work as part of the COVID Moonshot project which sought to create an orally bioavailable anti-viral for COVID-19. During the project, UCB completed six
Read More
30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021
As we close out the year, we asked several healthcare executives to share their predictions and trends for 2021.
Kimberly Powell, Vice President & General Manager, NVIDIA Healthcare
Federated Learning: The clinical community will increase their use of federated learning approaches to build robust AI models across various institutions, geographies, patient demographics, and medical scanners. The sensitivity and selectivity of these models are outperforming AI models
Read More
